× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.

meta|Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En Fr

Our approach

adjuvant therapies

anticoagulant 1

anticoagulant, curative dose 1

anticoagulant, pre-admission 3

anticoagulant, prophylactic dose 2

anti-inflammatoty and immuno-therapy

anti-inflammatory therapies

non-steroidal anti-inflammatory drugs 4

corticosteroids 1

Immunostimulants drugs

convalescent plasma treatment

neutralizing antibody

casirivimab/imdevimab (Ronapreve) 1

Immunosuppressants drugs

anti-interleukin-6

5-alpha-reductase inhibitors

antiviral and associated therapy

chloroquine and derivatives

hydroxychloroquine

hydroxychloroquine plus macrolides

lopinavir/ritonavir

Drugs for acid related disorders

proton pump inhibitors (PPI) 3

2-deoxy-D-glucose (2-DG)

calcium channel blocker

kinin-kallikrein inhibitors

ozonated autohemotherapy

Oral antidiabetic drugs

DPP-4 inhibitor

Renin-angiotensin-system-acting agents 1

angiotensin converting enzyme inhibitors (ACEIs)

angiotensin receptor blockers (ARBs)

BCG vaccination

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy -